Related Experiment Video
Updated: Jun 29, 2026
08:25
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
Published on: September 9, 2020
Cell-surface-bound circulating DNA as a prognostic factor in lung cancer
Svetlana N Tamkovich1, Nikolai V Litviakov, Olga E Bryzgunova
1Institute of Chemical Biology and Fundamental Medicine, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.
Annals of the New York Academy of Sciences
|October 8, 2008
Summary
Quantifying cell-surface-bound circulating DNA (csb-cirDNA) in non-small cell lung cancer patients can predict poor prognosis. Lower csb-cirDNA levels indicate a higher risk of unfavorable outcomes in lung cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Lung cancer has high mortality, necessitating improved prognostic tools for effective treatment.
- Current prognostic markers for non-small cell lung cancer (NSCLC) require enhancement.
- Circulating DNA (cirDNA) is being investigated as a potential biomarker.
Purpose of the Study:
- To evaluate the utility of circulating DNA (cirDNA) as a prognostic marker in non-small cell lung cancer (NSCLC).
- To compare plasma cirDNA and cell-surface-bound circulating DNA (csb-cirDNA) concentrations between NSCLC patients and healthy donors.
- To determine the correlation between csb-cirDNA levels and NSCLC prognosis.
Main Methods:
- Blood samples were collected from NSCLC patients and healthy donors.
- Plasma cirDNA concentrations were measured.
- Cell-surface-bound circulating DNA (csb-cirDNA) concentrations were quantified.
- Statistical analysis was performed to compare groups and assess correlations.
Main Results:
- Average plasma cirDNA levels were similar in NSCLC patients and healthy controls.
- Concentrations of cell-surface-bound circulating DNA (csb-cirDNA) were significantly lower in NSCLC patients compared to healthy donors (P < 0.0001).
- Lower csb-cirDNA levels correlated with a poor prognosis in NSCLC patients.
Conclusions:
- Cell-surface-bound circulating DNA (csb-cirDNA) is a promising prognostic marker for non-small cell lung cancer.
- Quantification of csb-cirDNA in untreated patients can identify individuals with a poor prognosis with high sensitivity (94%) and moderate specificity (50%).
- This biomarker may aid in tailoring therapeutic strategies for NSCLC.
